Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Medarex "Scils" a deal

Investors looking for validation of a biotech company's technology often rely on the reputation of its partners as surrogates for their own due diligence. But when the partner is a relative unknown name, a little more work

Read the full 372 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers